戻る
Moleculin Biotech Inc (MBRX)価格
MBRX 株価推移チャート
MBRX 収入
Moleculin Biotech Inc
$0
0%
$0
終値： Feb 18, 16:00:00 GMT-5
$0
0%
$0
アフターマーケット：Feb 18, 20:00:00 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-13
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
MBRXの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Moleculin Biotech Inc MBRXの前四半期の収益はどうでしたか？
Moleculin Biotech Incの収益見積もりはいくらですか？
Moleculin Biotech Incの収益品質スコアはどれくらいですか？
Moleculin Biotech Incはいつ収益を報告しますか？
Moleculin Biotech Incの予想収益はいくらですか？
Moleculin Biotech Incは収益予想を上回りましたか？
主要データ
前終値
--
始値
--
当日レンジ
-
52週レンジ
-
取引高
--
平均取引高
287.6K
1株当たり利益(TTM)
-46.92
配当利回り
--
時価総額
--
MBRXとは何ですか？
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Houston, Texas and currently employs 17 full-time employees. The company went IPO on 2016-06-02. The firm is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).